Tekla Life Sciences Investors(HQL)
USD --+0.00%
Reward68High
Risk22Low
📊75%Data
Strong 4416% profit margin · 10.8% dividend yield · Revenue down 70% YoY
HQL
+0.0 · +0.00%
USD · NYSE
Tekla Life Sciences Investors | Financial Services
Dividend King
Market Cap:497.26M
ℹ️
Reward Rating
68
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
22
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on HQL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Tekla Life Sciences Investors?

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc.

HQL · Verdict

Solid reward · low risk

HQL scores well on balance sheet and growth with no major weaknesses flagged in the model.

Based on 88% data coverage

HQL · Verdict

What’s working & what to watch

Strengths 5

  • Balance sheet94/100

    Current ratio 1.74

  • Growth85/100

    Top decile vs peers

  • Cash flow84/100

    37% free-cash-flow margin

  • Profitability69/100

    99% net margin · 18% ROE

  • Volatility65/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Tekla Life Sciences Investors?

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. The company is listed on the NYSE in USA, operating in the Financial Services sector, with a market capitalisation of 497.26M, and a P/E ratio of 6.0x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (68)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorFinancial Services
Market Cap497.26M
P/E Ratio6.0215
Dividend Yield10.82%
52 Week High17.1313
52 Week Low9.2823
Last AnnualSeptember
IPO Date5/4/1992
IncorporatedUSA
Shares Outstanding30M
No. of EmployeesN/A
IndustryAsset Management
ExchangeNYSE
Beta0.729
CurrencyUSD